Subscribe to our Email Alerts
Neuren Pharmaceuticals
  • Home
  • About Us
    • Company Overview
    • Company Values
    • Board of Directors
    • Executive Management
    • Corporate Directory
  • Products
    • DAYBUE™ (trofinetide)
  • Pipeline
    • Pipeline
    • Trofinetide
      • Rett Syndrome
    • NNZ-2591
      • Phelan-McDermid Syndrome
      • Angelman Syndrome
      • Pitt Hopkins Syndrome
      • Hypoxic-ischemic encephalopathy
      • Prader-Willi Syndrome
  • Science
    • Science Behind Neuren's Products
    • Trofinetide Published Studies & Presentations
      • Rett Syndrome
    • NNZ-2591Published Studies & Presentations
      • Phelan-McDermid Syndrome
      • Pitt Hopkins Syndrome
      • Angelman Syndrome
  • Investors
    • Investor Dashboard
    • Share Price Information
    • ASX Announcements
    • Annual and Interim Reports
    • Investor Presentations
    • Corporate Governance
    • Analyst Coverage
    • Shareholder Services
  • News & Media
    • Media
  • Contact
    • Contact Us
    • Email Alerts

Pipeline

Home > Pipeline > Pipeline
  • Pipeline
  • Trofinetide
    • Rett Syndrome
  • NNZ-2591
    • Phelan-McDermid Syndrome
    • Angelman Syndrome
    • Pitt Hopkins Syndrome
    • Hypoxic-ischemic encephalopathy
    • Prader-Willi Syndrome

Pipeline

Rett
Syndrome
Fragile X
Syndrome
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome

Quick Links

Contact Us

Neuren Pharmaceuticals Limited
Suite 201, 697 Burke Road
Camberwell, VIC 3124
Australia

Phone: +61 (3) 9092 0480
Email: enquiries@neurenpharma.com

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Neuren Pharmaceuticals
Site Map Privacy Search
Site by